Androgen receptor (AR) amplification in patients with metastatic castration-resistant prostate cancer (mCRPC) refractory to therapy with abiraterone acetate or enzalutamide: Preliminary results from the SU2C/PCF/AACR West Coast Prostate Cancer Dream Team (WCDT).
Eric Jay Small
Research Funding - Janssen-Ortho
Jack Youngren
No relevant relationships to disclose
George Thomas
No relevant relationships to disclose
Susan Olson
No relevant relationships to disclose
Alexandria Toschi
No relevant relationships to disclose
Adam Foye
No relevant relationships to disclose
Joshi J. Alumkal
No relevant relationships to disclose
Matthew Rettig
No relevant relationships to disclose
Martin Edwin Gleave
Consultant or Advisory Role - Astellas Pharma; Janssen
Research Funding - Astellas Pharma; Janssen
Christopher P. Evans
Consultant or Advisory Role - Astellas Pharma; Janssen
Research Funding - Astellas Pharma
Josh Stuart
No relevant relationships to disclose
Charles J. Ryan
No relevant relationships to disclose
Robert Evan Reiter
No relevant relationships to disclose
Kim N. Chi
No relevant relationships to disclose
Primo Lara
No relevant relationships to disclose
Tomasz M. Beer
Consultant or Advisory Role - Janssen
Research Funding - Astellas Pharma; Janssen